State: | New Jersey |
---|---|
Address: | 121 River St, Hoboken, NJ 07030 |
Zip code: | 07030 |
Phone: | (201) 604-1130 |
Website: | http://www.nuwiqusa.com/contact/ |
There are no reviews yet!
You can review this Business and help others by leaving a comment. If you want to share your thoughts about Nuwiq, use the form below and your opinion, advice or comment will appear in this space.
The phone number for Nuwiq is (201) 604-1130.
Nuwiq is located at 121 River St, Hoboken, NJ 07030
The website (URL) for Nuwiq is: http://www.nuwiqusa.com/contact/
P: 201-604-1130. Customer Service. For general questions about NUWIQ Antihemophilic Factor (Recombinant), reconstitution, product support, or this site, please contact Octapharma Customer Service.
P: 201-604-1130. Customer Service. What Octapharma product are you inquiring about?* Select One Wilate NUWIQ. Please describe your medical inquiry below.
LACHEN, Switzerland--(BUSINESS WIRE)--Octapharma announced today that the European Medicines Agency has authorised an updated Summary of Product Characteristics (SmPC) for Nuwiq® that includes information on personalised prophylaxis in patients with haemophilia A. The updated...
Nuwiq® is indicated for the treatment and prophylaxis of bleeding in persons with hemophilia of all ages suffering with hemophilia A (congenital factor VIII deficiency). Nuwiq® can also be used in hemophilia A patients undergoing major or minor surgical procedures.
P: 201-604-1137 C: 201-772-4546 F: 201-604-1141. Medical Affairs. Phone*. What Octapharma product are you inquiring about?* Select One cutaquig NUWIQ wilate. Please describe your medical inquiry below.
Octapharma USA, Inc. 121 River Street, Suite 1201 Hoboken, NJ 07030 (201) 604-1130. Nuwiq Generic name: antihemophilic factor Drug class: miscellaneous coagulation modifiers.
Fax: (201) 604-1131. usmedicalaffairs@octapharma.com. NUWIQ. Bleeding disorders. OCTAGAM.
Fax: (201) 604-1131. usmedicalaffairs@octapharma.com. www.octapharma.com. Drugs. NUWIQ. Bleeding disorders.
NUWIQ ® is approved for the prevention and treatment of bleeding in people with haemophilia A. The updated PI includes immunogenicity data from the NuProtect study in previously untreated patients (PUPs).
Nuwiq® is produced in a human embryonic kidney cell line (HEK293F), which ensures human-specific post-translational protein processing. The mean half-life of Nuwiq® was 15.1-17.1 h in PTP studies with adults and adolescents, and 12.5 h in children aged 2-12 years.